Related Experiment Video
Updated: Dec 23, 2025
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
Dihydroouabain, a novel radiosensitizer for cervical cancer identified by automated high-throughput screening
Zhihao Li1, Keisuke Tamari1, Yuji Seo1
1Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Background And Purpose:
Radiotherapy plays a crucial role in the treatment of cervical cancer, but existing radiosensitizers have limited efficacy in clinical applications. The aims of this study were to establish and verify an efficient method for identifying new radiosensitizers, to use this to identify candidate radiosensitizers for cervical cancer, and to investigate the specific mechanisms of these when used in combination with radiotherapy.
Materials And Methods:
An automated platform for identifying radiosensitizers for cervical cancer was created based on high-throughput screening technology. The radiosensitizing effects of candidate compounds from the LOPAC1280 chemical library were evaluated in radiosensitive and radioresistant cervical cancer cells using a clonogenic survival assay, with cell cycle analyses, and western blot analyses performed for both cell lines.
Results:
The automated high-throughput screening approach identified four hit compounds. One of the most potent candidates was dihydroouabain (DHO), an inhibitor of Na+/K+-ATPase that has not previously been classified as a radiosensitizer. DHO significantly enhanced radiosensitivity in cervical cancer cells. It also abrogated radiation-induced S phase arrest in cervical cancer cells. Combination treatment significantly caused the inhibition of Chk1 and increased DNA double-strand breaks (DSB).
Conclusions:
DHO is a novel radiosensitizer for the treatment of cervical cancer. The automated high-throughput screening platform developed in this study proved to be powerful and effective, with the potential to be widely used in the future identification of radiosensitizers.
Insights
This study developed an automated platform to identify new radiosensitizers for cervical cancer. Dihydroouabain (DHO) was identified as a potent radiosensitizer, enhancing treatment efficacy by increasing DNA damage.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Radiotherapy is vital for cervical cancer treatment, but current radiosensitizers show limited clinical effectiveness.
- Developing novel radiosensitizers is crucial to improve treatment outcomes.
Purpose of the Study:
- Establish and validate an efficient method for identifying new radiosensitizers.
- Identify candidate radiosensitizers for cervical cancer.
- Investigate the mechanisms of radiosensitizers combined with radiotherapy.
Main Methods:
- Developed an automated high-throughput screening platform for radiosensitizer identification.
- Evaluated radiosensitizing effects using clonogenic survival assays in cervical cancer cells.
- Conducted cell cycle and western blot analyses to understand mechanisms.
Main Results:
- Identified four hit compounds, including dihydroouabain (DHO), a novel radiosensitizer.
- DHO significantly enhanced radiosensitivity and abrogated radiation-induced S phase arrest.
- Combination therapy with DHO inhibited Chk1 and increased DNA double-strand breaks (DSB).
Conclusions:
- Dihydroouabain (DHO) is a novel radiosensitizer for cervical cancer.
- The automated high-throughput screening platform is effective for future radiosensitizer discovery.
